Inhibrx Biosciences (INBX)
Develops biologic drug candidates led by ozekibart and INBRX-106.
Something off on this page? Send us feedback.
Develops clinical-stage biologic drug candidates from the post-Sanofi Inhibrx platform, led by ozekibart and INBRX-106. With no marketed products and one reportable segment, the business depends on clinical execution, FDA review, and eventual commercialization.
Develops biologic therapeutic candidates from the post-Sanofi Inhibrx platform, with ozekibart and INBRX-106 as the active clinical programs. The business is organized as one reportable segment and has no marketed products.
Ozekibart is the most advanced asset after FDA acceptance of its biologics license application for unresectable or metastatic conventional chondrosarcoma. INBRX-106 is an OX40 agonist studied with pembrolizumab in head and neck cancer and other solid tumors.
Operates from La Jolla with an R&D-heavy workforce and founder Mark P. Lappe still serving as chief executive. The business depends on clinical execution, FDA review, and eventual commercialization rather than recurring product revenue.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 24, 2026 | H.C. Wainwright | Initiate | Rating: —Target: — | Target: $245 |
| May 15, 2026 | Stifel Nicolaus | Target | Target: — | Target: $325 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $133.3M · Total debt $5.3M · Total assets $154.2M · Shareholders' equity −$53.0M
- Revenue
- $0
- Operating income
- −$32.1M
- Net income
- −$36.7M
| Institutions | ≈ 97.01% | 14.28M shares | |
|---|---|---|---|
| 178 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 15.45% | 2.27M shares | |
| 5 holders · as of Sep 17, 2026 | |||
| Adds to | 112.46% | ||
14.72M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 112.46%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Morgan StanleyInstitution | 8.89% | 1.31M | as of Jun 30, 2026 |
Perceptive Advisors LLCInstitution | 8.82% | 1.30M | as of Jun 30, 2026 |
SanofiInstitution | 7.87% | 1.16M | as of Jun 30, 2026 |
Viking Global Investors LPInstitution | 7.64% | 1.12M | as of Jun 30, 2026 |
Jon Faiz Kayyem1Insiderdirector | 7.26% | 1.15M | filed Sep 17, 2026 |
- Jon Faiz Kayyem's transaction reports restate only vehicles that traded; the 2025 ownership statement (1.15M) less the 80.0K net shares sold since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Jon Faiz Kayyem | director | +5,000 | $100.00 |
| Sep 15, 2026 | Kimberly Manhard | director | −500 | $105.05 |
| Sep 14, 2026 | Kimberly Manhard | director | −500 | $110.26 |
| Sep 11, 2026 | Kimberly Manhard | director | −500 | $111.78 |
| Sep 9, 2026 | Kimberly Manhard | director | −500 | $115.80 |
- Merck
Keytruda benchmark for first-line HNSCC checkpoint combinations
- Bicara Therapeutics
Late-stage ficerafusp alfa challenger in first-line HNSCC
- Bristol-Myers Squibb
Opdivo checkpoint franchise across HNSCC and solid tumors
- PDS Biotechnology
Versamune HPV checkpoint-combination program in HPV16+ HNSCC
- Cogent Biosciences
Rare solid-tumor precision therapy peer in GIST
- Cue Biopharma
CUE-101 T-cell engager program in HPV16+ HNSCC
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences | $103.10 | −6.84% | $1.62B | — | — | — | — |
| Merck | $147.28 | −2.41% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| Bicara Therapeutics | $21.46 | −5.81% | $1.50B | — | — | — | — |
| Bristol-Myers Squibb | $61.76 | −0.79% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| PDS Biotechnology | $0.8414 | −7.54% | $50.9M | — | — | — | — |
| Cogent Biosciences | $31.01 | −4.98% | $5.58B | — | — | — | — |
| Cue Biopharma | $32.62 | +5.57% | $81.2M | — | — | 2.2 | +166.7% |
| Median | 67.2 | 13.4 | 2.6 | +5.7% |